Published 6 days ago • loading... • Updated 6 days ago

Data readout puts J&J's bladder cancer drug back on track

Summary by Pharmaphorum

New data in non-muscle-invasive bladder cancer (NMIBC) has backed up Johnson & Johnson's faith in its TAR-200 drug candidate.

1 Articles

All

Left

Center

Right

New data in non-muscle-invasive bladder cancer (NMIBC) has backed up Johnson & Johnson's faith in its TAR-200 drug candidate.

6 days ago

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Total News Sources1

Leaning Left0Leaning Right0Center1Last Updated5 days agoBias Distribution

100% Center

100% Center

Factuality

To view factuality data please Upgrade to Premium

To view ownership data please Upgrade to Vantage

Pharmaphorum broke the news in 6 days ago on Tuesday, April 22, 2025.

Sources are mostly out of (0)